June 2022
Volume 63, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2022
Profile of age-related macular degeneration in Bhutan: Should screening be considered?
Author Affiliations & Notes
  • Bhim Bahadur Rai
    Neuroscience, Australian National University The John Curtin School of Medical Research, Canberra, Australian Capital Territory, Australia
    Ophthalmology, JDW National Referral Hospital, Thimphu, Thimphu, Bhutan
  • Michael G. Morley
    Ophthalmology, OCB, Boston, Massachusetts, United States
    Harvard Medical School, Boston, Massachusetts, United States
  • Paul S Bernstein
    Ophthalmology, University of Utah Health John A Moran Eye Center, Salt Lake City, Utah, United States
  • Ted Maddess
    Neuroscience, Australian National University The John Curtin School of Medical Research, Canberra, Australian Capital Territory, Australia
  • Footnotes
    Commercial Relationships   Bhim Rai None; Michael Morley None; Paul Bernstein None; Ted Maddess None
  • Footnotes
    Support  ANU PhD Scholarship
Investigative Ophthalmology & Visual Science June 2022, Vol.63, 368 – F0199. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Bhim Bahadur Rai, Michael G. Morley, Paul S Bernstein, Ted Maddess; Profile of age-related macular degeneration in Bhutan: Should screening be considered?. Invest. Ophthalmol. Vis. Sci. 2022;63(7):368 – F0199.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To determine the severity of age-related macular degeneration (AMD) at first presentation among the Bhutanese patients attending vitreoretinal (VR) clinics and to inform national health policy on the potential benefits of a screening program.

Methods : A retrospective cross-sectional consecutive case series study was conducted on new AMD cases. If a patient presented with asymmetrical AMD, the eye with more severe AMD was considered. If both the eyes had the same severity one eye was chosen randomly. Collection of demographic data and clinical details including diagnostic testing (fundus photography, OCT and fluorescent angiography) and clinical staging were performed.

Results : Of 521 new AMD patients aged 71.9 ± 11.3 years, 306 (58.7%) were males (p=0.005). At their first presentation, 234 patients (44.9%) already had late-stage AMD. Importantly, 69 patients (29.5%), that is half of total neovascular AMD (nAMD) patients, had disciform scars (DS) which were beyond treatment, and 7 (3.0%) had geographic atrophy (GA). Fourteen of nineteen polypoidal choroidal vasculopathy (PCV) patients were younger than 50 years.

Conclusions : Half of total nAMD cases presented as DS not amenable to the treatment. Many potentially treatable patients with nAMD had already lost central vision and were legally blind. Young people with PCV losing vision early in life with longer morbidity-affected life and socio-economic burden was concerning. GA and DS cases need visual rehabilitation to improve their QoL. Incorporating a screening program for AMD with effective health education, and maintaining a national AMD Registry, would potentially lower AMD-related blindness and visual impairment.

This abstract was presented at the 2022 ARVO Annual Meeting, held in Denver, CO, May 1-4, 2022, and virtually.

 

Figure 1. Probability histogram plots by gender. A) Disciform scar group: a higher proportion of older females are seen in this group than in B) Neovascular AMD group.

Figure 1. Probability histogram plots by gender. A) Disciform scar group: a higher proportion of older females are seen in this group than in B) Neovascular AMD group.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×